SSX2
| SSX2 | ||
|---|---|---|
| other names |
|
|
| Properties of human protein | ||
| Identifier | ||
| Gene name | SSX2 | |
| External IDs | ||
| Occurrence | ||
| Homology family | HOG000231461 | |
SSX2 ( English Synovial sarcoma, X breakpoint 2 , also Cancer / testis antigen 5.2 , tumor antigen HOM-MEL-40 ) is a human tumor antigen from the group of the cancer testis antigens .
properties
SSX2 is 188 amino acids long and has a mass of 21,620 Da . It has phosphorylated serines at positions 108 and 123. SSX2 results from a translocation of chromosomes 18 and X , more precisely from the synovial sarcoma translocation gene and a gene of the SSX family, which results in an oncogenic fusion protein . SSX2 comes as a tumor antigen not in healthy cells before (except in immune privileged spermatocytes ), but often in different tumors expressing such. B. Prostate cancer and synovial sarcoma . It is therefore a target antigen in the development of cancer vaccines and cancer immunotherapies with adoptive cell transfer .
Individual evidence
- ↑ JE Bloom, DG McNeel: SSX2 Regulates focal adhesion but does not drive the epithelial to mesenchymal transition in prostate cancer. In: Oncotarget. [Electronic publication before printing] June 2016, doi: 10.18632 / oncotarget.9802 , PMID 27276714 .
- ↑ M. Tagliamonte, A. Petrizzo, ML Tornesello, FM Buonaguro, L. Buonaguro: Antigen-specific vaccines for cancer treatment. In: Human vaccines & immunotherapeutics. Volume 10, number 11, 2014, pp. 3332–3346, doi: 10.4161 / 21645515.2014.973317 , PMID 25483639 , PMC 4514024 (free full text).